Fig. 7: Single-cell RNAseq analysis of migratory DCs in mLN following i.n immunizations with a CD103-targeted adjuvant. | Mucosal Immunology

Fig. 7: Single-cell RNAseq analysis of migratory DCs in mLN following i.n immunizations with a CD103-targeted adjuvant.

From: ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection

Fig. 7

Migratory cDC-subsets that had been exposed to a single dose i.n of 50 μM CD103 or -DD constructs with incorporated Eα-peptide were identified by labeled Yea-Mab that binds Eα−peptide + MHC class II (I-Ab)39. This strategy secured that only cDCs exposed to CTA1-adjuvant in vivo were included in the analysis and these were compared to cDCs from unimmunized mice. Migratory cDCs were sorted by FACS and subjected to a scRNAseq analysis using the 10× Chromium platform. Cluster analysis was performed using Seurat and the UMAP-representation of the cDC-subsets from naïve PBS, CTA1-II-DD or CTA1-II-CD103 treated mice is depicted and the cluster or treatment distributions of individual cDCs is given (a, b). Distribution of cDC1 and cDC2 cells among the analyzed cDCs, according to the UMAP, based on cDC1 and cDC2 subset-restricted gene definitions (c). Heat map showing the 25 top DEG in the different clusters of migratory cDCs following immunization (d). Top 20 differentially expressed genes (DEG) in CTA1-exposed (DD- + CD103 constructs) as opposed to unimmunized cDC1 (left panels) and cDC2 subsets (right panels) (e).

Back to article page